Showing 1,461 - 1,480 results of 2,209 for search '"Chengdu"', query time: 0.05s Refine Results
  1. 1461
  2. 1462
  3. 1463

    Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial by Liu Y, Li X, Zhang M, Men Y, Wang Y, Zhu X, Zheng L

    Published 2025-01-01
    “…Yixian Liu,1,2,* Xiaoyu Li,1,2,* Mengyu Zhang,1,2 Yuchun Men,1,2 Ying Wang,1,2 Xiaohong Zhu,1,2 Li Zheng1,2 1Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China; 2Clinical Trial Center, NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China*These authors contributed equally to this workCorrespondence: Li Zheng, Cancer Center, West China Hospital, Sichuan University, No. 5 Telecom Road, Wuhou District, Chengdu, 610041, People’s Republic of China, Email zhengli@wchscu.cnPurpose: HA121-28, a novel multi-targeting tyrosine kinase inhibitor, has dual efficacy against tumor growth and neovascularization. …”
    Get full text
    Article
  4. 1464
  5. 1465
  6. 1466
  7. 1467
  8. 1468
  9. 1469
  10. 1470
  11. 1471
  12. 1472
  13. 1473
  14. 1474
  15. 1475
  16. 1476
  17. 1477
  18. 1478
  19. 1479
  20. 1480